サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1348060

臨床試験の世界市場：相別、サービスタイプ別、治療領域別、用途別-2028年までの予測

Clinical Trials Market by Phase, Service Type, Therapeutic Area, and Application - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 342 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
臨床試験の世界市場：相別、サービスタイプ別、治療領域別、用途別-2028年までの予測
出版日: 2023年09月08日
発行: MarketsandMarkets
ページ情報: 英文 342 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の臨床試験の市場規模は、2023年の482億米ドルから2028年には732億米ドルに達すると予測され、2023年から2028年の予測期間中のCAGRは8.7%と見込まれています。

同市場の成長は、特殊な検査サービスに対する需要の増加に起因しています。企業は、液体クロマトグラフィー質量分析法（LC/MS）、RNAシーケンス、遺伝子発現分析、コンペンディア原料の湿式化学分析、誘導結合質量分析法（ICP-MS）による微量金属分析など、特殊な検査サービスのアウトソーシングをますます進めています。これらの検査には高度な機器と熟練した専門家が必要です。設備や人件費を削減するため、製薬企業やバイオ医薬品企業は、これらの専門的な検査サービスをCRO（医薬品開発業務受託機関）にアウトソーシングすることを好んでいます。

2022年、世界の臨床試験市場において、低分子セグメントは用途別で最大のシェアを占めました。低分子は、心血管疾患から感染症、癌に至るまで、幅広い治療領域をカバーしています。この汎用性により、さまざまな病態にわたる多様な臨床試験が可能になります。低分子の開発プロセスは確立されており、米国FDAのような規制機関に理解されています。このような慣れが承認プロセスを迅速化し、製薬会社がこれらの化合物の臨床試験に投資することを促しています。このような要因が、2022年の同分野の優位性に寄与しています。

2022年の北米の臨床試験市場は米国が支配しました。米国の臨床試験市場が大きなシェアを占めているのは、同国で実施される臨床試験や創薬活動の数が多いことに加え、製薬・バイオ医薬品部門に最先端の研究開発インフラが整備されているためです。米国は臨床試験の世界のハブとして機能しており、医薬品開発研究の大部分は米国で実施されています。この動向は、強固な規制の枠組みと高度に発達した病院インフラに起因しています。2023年8月現在、登録された臨床試験は世界で463,610件に達しています。注目すべきは、このうち3分の1を占める165,148件の登録臨床研究が米国内で終了していることです。

当レポートでは、世界の臨床試験市場について調査し、相別、サービスタイプ別、治療領域別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • バリューチェーン分析
  • 参考価格分析
  • エコシステム分析
  • 技術分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 主要な会議とイベント（2023-2024）
  • 主要な利害関係者と購入基準

第6章 臨床試験市場、相別

  • イントロダクション
  • 第Ⅲ相
  • 第II相
  • 第IV相
  • 第I相

第7章 臨床試験市場、サービスタイプ別

  • イントロダクション
  • 研究サービス
  • 生物分析検査サービス
  • 分散型臨床試験サービス
  • 被験者募集サービス
  • サイト識別サービス
  • 分析試験サービス
  • 供給および物流サービス
  • プロトコル設計サービス
  • データ管理サービス
  • 医療機器試験サービス
  • その他

第8章 臨床試験市場、治療領域別

  • イントロダクション
  • 腫瘍学
  • 感染症
  • 神経学
  • 代謝異常症
  • 免疫学
  • 心臓病
  • 遺伝病
  • 女性の健康
  • その他

第9章 臨床試験市場、用途別

  • イントロダクション
  • 低分子
  • モノクローナル抗体
  • ワクチン
  • 細胞および遺伝子治療
  • その他

第10章 臨床試験市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • イントロダクション
  • 主要参入企業戦略/有力企業
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス、2022年
  • 上位25社の企業フットプリント分析
  • 新興企業/中小企業の企業評価マトリックス、2022年
  • 新興企業/中小企業の競合ベンチマーキング
  • 競合シナリオと動向

第12章 企業プロファイル

  • 主要企業
    • THERMO FISHER SCIENTIFIC, INC.
    • IQVIA, INC.
    • ICON PLC
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • SYNEOS HEALTH
    • WUXI APPTEC
    • CHARLES RIVER LABORATORIES
    • PAREXEL INTERNATIONAL CORPORATION
    • FORTREA, INC.
    • MEDPACE
    • SGS
    • FRONTAGE LABS
    • ACM GLOBAL LABORATORIES
    • ADVANCED CLINICAL
    • PSI
    • BIOAGILE
  • その他の企業
    • CLINICAL TRIAL SERVICE
    • WORLDWIDE CLINICAL TRIALS
    • PEPGRA
    • CTI CLINICAL TRIAL AND CONSULTING SERVICES
    • DOVE QUALITY SOLUTIONS
    • FIRMA CLINICAL RESEARCH
    • CELERION
    • NOVOTECH
    • LINICAL AMERICAS

第13章 付録

目次
Product Code: PH 1622

The global clinical trials market is projected to reach USD 73.2 billion by 2028 from USD 48.2 billion in 2023, at a CAGR of 8.7% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing demand for specialized testing services. Companies are increasingly outsourcing specialized testing services, such as liquid chromatography-mass spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, and trace metal analysis with inductively coupled mass spectrometry (ICP-MS). These tests require advanced equipment and skilled professionals. In an effort to reduce equipment and labor expenses, pharmaceutical and biopharmaceutical enterprises prefer the outsourcing of these specialized testing services to Contract Research Organizations (CROs).

"The small molecules segment accounted for the largest share by application in 2022."

In 2022, the small molecules segment accounted for the largest share by application in the global clinical trials market. Small molecules cover a wide spectrum of therapeutic areas, from cardiovascular diseases to infectious diseases to cancer. This versatility allows for a diverse range of clinical trials across different medical conditions. The development process for small molecules is well-established and understood by regulatory agencies like the US FDA. This familiarity expedites the approval process and encourages pharmaceutical companies to invest in clinical trials for these compounds. These factors contributed to the dominance of the segment in 2022.

"The US has continued to dominate the clinical trials market during the forecast period of 2023-2028."

The US dominated the clinical trials market in North America in 2022. The major share of the US clinical trials market can be attributed to the significant number of clinical trials and drug discovery activities conducted in the country, coupled with the presence of state-of-the-art research and development infrastructure within the pharmaceutical and biopharmaceutical sectors. The US serves as a global hub for clinical trials, with a significant portion of drug development research being carried out in the US. This trend is attributed to its robust regulatory framework and highly advanced hospital infrastructure. According to ClinicalTrials.gov, as of August 2023, the global count of registered clinical studies reached 463,610. Notably, one-third of this total, accounting for 165,148 registered clinical studies, were concluded within the US.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 40% and Demand Side 60%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • IQVIA Inc. (US)
  • Laboratory Corporation of America Holdings (US)
  • Syneos Health (US)
  • WuXi AppTec (China)
  • Charles River Laboratories (US)
  • Parexel International Corporation (US)
  • Thermo Fisher Scientific Inc. (US)
  • ICON plc (Ireland)
  • Medpace (US)
  • ACM Global Laboratories (US)
  • Advanced Clinical (US)
  • SGS (Switzerland)
  • Frontage Labs (US)
  • PSI (Switzerland)
  • Bioagile (India)
  • Fortrea Inc. (US)
  • Clinical Trial Service (Netherlands)
  • Worldwide Clinical Trials (US)
  • Pepgra (UK)
  • CTI Clinical Trial & Consulting (US)
  • Dove Quality Solutions (UK)
  • Firma Clinical Research (US)
  • Celerion (US)
  • Novotech (Australia)
  • Clinical Americas (Japan)

Research Coverage:

This research report categorizes the clinical trials market by phase (Phase III, Phase II, Phase IV, and Phase I), by Service Type (Laboratory Services, Bioanalytical Testing Services, Decentralized Clinical Trial Services, Patient Recruitment, Site Identification, Analytical Testing Services, Clinical Trial Supply & Logistic Services, Protocol Designing, Clinical Trial Data Management Services, Medical Device Testing Services, and Other Services), by Therapeutic Area (Oncology, Infectious Diseases, Neurology, Metabolic Disorders, Immunology, Cardiology, Genetic Diseases, Women's Health, and Others) by Application (Small Molecules, Monoclonal Antibodies, Vaccine, Cell & Gene Therapy, and Others) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, trends, challenges, and opportunities, influencing the growth of the clinical trials market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services, key strategies, collaborations, partnerships, and agreements. New launches, mergers and acquisitions, and recent developments associated with the clinical trials market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trials market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing drugs in the pipeline, rising investments in pharmaceutical R&D, and increasing number of clinical trials), restraints (Shortage of skilled professionals for clinical trials, Need for unique testing approaches for innovative molecules), opportunities (Favorable outlook for biologics and biosimilars and Rising demand for specialized testing services), and Trends (Adoption of AI-based tools for drug discovery) influencing the growth of the market.
  • Service Development/Innovation: Detailed insights on newly launched services of the clinical trials market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trials market
  • Competitive Assessment: In- IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Syneos Health (US), WuXi AppTec (China), Charles River Laboratories (US), Parexel International Corporation (US), Thermo Fisher Scientific Inc. (US), ICON plc (Ireland), Medpace (US), ACM Global Laboratories (US), Advanced Clinical (US), SGS (Switzerland), Frontage Labs (US), PSI (Switzerland), Bioagile (India), Fortrea Inc. (US), and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF IQVIA: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, THERAPEUTIC AREA, AND APPLICATION)
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    • 2.2.3 SEGMENT ASSESSMENT (BY PHASE, SERVICE TYPE, AND THERAPEUTIC AREA)
  • 2.3 GROWTH FORECAST
    • FIGURE 8 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2023-2028
    • FIGURE 9 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 CLINICAL TRIALS MARKET: RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 CLINICAL TRIALS MARKET, BY PHASE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CLINICAL TRIALS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL TRIALS MARKET OVERVIEW
    • FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
  • 4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2022)
    • FIGURE 17 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2022
  • 4.3 BIOANALYTICAL SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION)
    • FIGURE 18 CELL-BASED ASSAYS TO DOMINATE MARKET TILL 2028
  • 4.4 CLINICAL TRIALS MARKET SHARE, BY THERAPEUTIC AREA, 2023-2028
    • FIGURE 19 ONCOLOGY TO HOLD LARGEST MARKET SHARE TILL 2028
  • 4.5 CLINICAL TRIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 CLINICAL TRIALS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing drugs in pipeline and rising investments in pharmaceutical R&D
    • FIGURE 22 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028
    • FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2023
      • 5.2.1.2 Increasing number of clinical trials
    • FIGURE 24 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2022)
      • 5.2.1.3 High cost of in-house drug development
    • FIGURE 25 DISTRIBUTION OF IN-HOUSE AND OUTSOURCING SERVICES EXPENDITURE IN GLOBAL PHARMA MARKET, 2014-2023 (% DISTRIBUTION)
      • 5.2.1.4 Rising prevalence of orphan and rare diseases
    • FIGURE 26 OVERVIEW OF TOP 20 COMPANIES FOCUSING ON RARE DISEASES (AS OF 2023)
    • FIGURE 27 PERCENTAGE OF NEW ACTIVE SUBSTANCES LAUNCHES WITH ORPHAN DRUG DESIGNATION, 2012-2022
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Favorable outlook for biologics and biosimilars
    • FIGURE 28 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2015-2022)
    • TABLE 5 LIST OF BIOLOGICS APPROVED BY US FDA, 2022
    • FIGURE 29 BIOSIMILAR APPROVALS AND LAUNCHES, 2015-2022
      • 5.2.2.2 Rising demand for specialized testing services
      • 5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
    • FIGURE 30 NUMBER OF ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (AS OF APRIL 2023)
    • FIGURE 31 GENE AND CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENTS, BY REGION (AS OF 2022)
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Shortage of skilled professionals for clinical trials
      • 5.2.3.2 Need for unique testing approaches for innovative molecules
    • 5.2.4 TRENDS
      • 5.2.4.1 Adoption of AI-based tools for drug discovery
      • 5.2.4.2 Increasing outsourcing activities in emerging Asian economies
      • 5.2.4.3 Integrated end-to-end R&D service solutions
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • FIGURE 32 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 33 VALUE CHAIN ANALYSIS OF CLINICAL TRIALS
  • 5.5 INDICATIVE PRICING ANALYSIS
    • TABLE 6 PHASE 3 ONCOLOGY CLINICAL TRIAL COST (US AND EUROPEAN COUNTRIES)
    • TABLE 7 PHASE I ONCOLOGY CLINICAL TRIAL COST (SPAIN-EUROPE)
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 34 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET
    • TABLE 8 OVERALL MARKET ECOSYSTEM FOR CLINICAL TRIALS
  • 5.7 TECHNOLOGY ANALYSIS
    • FIGURE 35 IMPORTANCE OF TECHNOLOGY ADOPTION IN CLINICAL TRIALS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 9 CLINICAL TRIALS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 CLINICAL TRIALS MARKET REGULATORY SCENARIO, BY COUNTRY/REGION
  • 5.10 KEY CONFERENCES AND EVENTS (2023-2024)
    • TABLE 15 CLINICAL TRIALS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2023-2024)
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIALS
    • 5.11.2 BUYING CRITERIA FOR CLINICAL TRIALS
    • FIGURE 37 KEY BUYING CRITERIA FOR END USERS

6 CLINICAL TRIALS MARKET, BY PHASE

  • 6.1 INTRODUCTION
    • TABLE 16 CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • FIGURE 38 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2021 VS. 2022
  • 6.2 PHASE III
    • 6.2.1 RISING PRICES OF PHASE III TRIALS TO DRIVE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
    • TABLE 17 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE III (2021-2022)
    • TABLE 18 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 19 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 PHASE II
    • 6.3.1 LONG DURATION OF PHASE II STUDIES TO PROVIDE GROWTH OPPORTUNITIES FOR CROS
    • TABLE 22 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE II (2021-2022)
    • TABLE 23 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 PHASE IV
    • 6.4.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE MARKET
    • TABLE 27 OVERVIEW OF DRUGS THAT HAVE COMPLETED PHASE IV (2021-2022)
    • TABLE 28 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 29 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 PHASE I
    • 6.5.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES TO BOOST MARKET
    • TABLE 32 OVERVIEW OF DRUGS IN PHASE I STUDIES (2021-2022)
    • TABLE 33 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 CLINICAL TRIALS MARKET, BY SERVICE TYPE

  • 7.1 INTRODUCTION
    • TABLE 37 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
  • 7.2 LABORATORY SERVICES
    • 7.2.1 RISING IMPORTANCE OF LAB SERVICES AND NEED TO ENSURE REGULATORY COMPLIANCE TO DRIVE MARKET
    • TABLE 38 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
    • TABLE 39 LABORATORY SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 BIOANALYTICAL TESTING SERVICES
    • TABLE 43 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 44 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.1 CELL-BASED ASSAYS
      • 7.3.1.1 Rising number of providers offering customized assay testing to boost growth
    • TABLE 48 CELL-BASED ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.2 VIROLOGY TESTING
      • 7.3.2.1 Rising uptake of in vitro virology assays to develop antiviral pharmaceuticals to favor market
    • TABLE 52 VIROLOGY TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.3 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES
      • 7.3.3.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to drive market
    • TABLE 56 SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, AND NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.4 PK/PD TESTING
      • 7.3.4.1 Growing importance of drug pharmacokinetics to boost demand
    • TABLE 60 PK/PD TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: PK/PD TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: PK/PD TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: PK/PD TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.5 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION
      • 7.3.5.1 Biopharma industry preference for outsourcing method validation to drive market
    • TABLE 64 METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 66 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, AND VALIDATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.6 BIOMARKER TESTING
      • 7.3.6.1 Growing emphasis on biomarker testing to develop personalized medicines and CDx to augment market
    • TABLE 68 BIOMARKER TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 69 NORTH AMERICA: BIOMARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 EUROPE: BIOMARKER TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.7 OTHER BIOANALYTICAL TESTING SERVICES
    • TABLE 72 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 DECENTRALIZED CLINICAL TRIAL SERVICES
    • 7.4.1 HIGH DEMAND FOR DCT ATTRIBUTED TO ADVANCEMENTS IN DIGITAL HEALTH TECHNOLOGIES
    • TABLE 76 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 PATIENT RECRUITMENT SERVICES
    • 7.5.1 GROWING NEED FOR PATIENT-CENTRIC CLINICAL TRIAL SERVICES TO SUPPORT DEMAND
    • TABLE 80 OVERVIEW OF PATIENT RECRUITMENT SERVICE PROVIDERS
    • TABLE 81 PATIENT RECRUITMENT SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 82 NORTH AMERICA: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 EUROPE: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: PATIENT RECRUITMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.6 SITE IDENTIFICATION SERVICES
    • 7.6.1 INTRODUCTION OF DIGITAL TECHNOLOGIES ENABLING DATA VARIABILITY TO DRIVE MARKET
    • TABLE 85 SITE IDENTIFICATION SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 86 NORTH AMERICA: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 EUROPE: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: SITE IDENTIFICATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.7 ANALYTICAL TESTING SERVICES
    • 7.7.1 INCREASING DEMAND FOR ANALYTICAL TESTING IN DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 89 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 90 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.8 SUPPLY & LOGISTICS SERVICES
    • 7.8.1 USAGE OF ADVANCED DATA ANALYTICS IN CLINICAL TRIAL SUPPLY MANAGEMENT TO DRIVE MARKET
    • TABLE 93 SUPPLY & LOGISTICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 94 NORTH AMERICA: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 EUROPE: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: SUPPLY & LOGISTICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.9 PROTOCOL DESIGNING SERVICES
    • 7.9.1 NEED FOR PLANNING SUPPORT TO BOOST DEMAND FOR PROTOCOL DESIGN
    • TABLE 97 PROTOCOL DESIGNING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 98 NORTH AMERICA: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: PROTOCOL DESIGNING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.10 DATA MANAGEMENT SERVICES
    • 7.10.1 DATA MANAGEMENT SERVICES TO RECORD HIGHEST CAGR OVER FORECAST PERIOD
    • TABLE 101 DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
    • TABLE 102 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 103 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.11 MEDICAL DEVICE TESTING SERVICES
    • 7.11.1 INCREASING MEDICAL DEVICE R&D TO DRIVE MARKET
    • TABLE 106 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 107 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.12 OTHER SERVICES
    • TABLE 110 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 111 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA

  • 8.1 INTRODUCTION
    • TABLE 114 CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 8.2 ONCOLOGY
    • 8.2.1 ONCOLOGY TO DOMINATE MARKET DUE TO RISING INCIDENCE OF CANCER
    • FIGURE 39 US CANCER INCIDENCE IN MALES, BY TYPE (2022)
    • FIGURE 40 US CANCER INCIDENCE IN FEMALES, BY TYPE (2022)
    • FIGURE 41 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2021 (THOUSAND)
    • TABLE 115 NEW FDA-APPROVED ONCOLOGY DRUGS (2023)
    • TABLE 116 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 INFECTIOUS DISEASES TO HOLD SECOND-LARGEST MARKET SHARE, BY THERAPEUTIC AREA
    • TABLE 120 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 121 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 123 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 NEUROLOGY
    • 8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET
    • TABLE 124 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
    • TABLE 125 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 126 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.5 METABOLIC DISORDERS
    • 8.5.1 RISING DIABETES INCIDENCE TO DRIVE MARKET
    • FIGURE 42 INCREASE IN DIABETES CASES, 2000-2045 (MILLION INDIVIDUALS)
    • TABLE 129 CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 130 NORTH AMERICA: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 EUROPE: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.6 IMMUNOLOGY
    • 8.6.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS TO BOOST OUTSOURCING
    • TABLE 133 LIST OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS (2022)
    • TABLE 134 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.7 CARDIOLOGY
    • 8.7.1 HIGH MORTALITY RATES TO DRIVE DEVELOPMENT OF NEW TREATMENTS
    • TABLE 138 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2023)
    • TABLE 139 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 140 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.8 GENETIC DISEASES
    • 8.8.1 GOVERNMENT SUPPORT FOR RARE & GENETIC DISEASE THERAPEUTICS TO BOOST MARKET
    • TABLE 143 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 144 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 145 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.9 WOMEN'S HEALTH
    • 8.9.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL DEMAND
    • TABLE 147 CLINICAL TRIALS MARKET FOR WOMEN'S HEALTH, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 148 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN'S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 149 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN'S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN'S HEALTH, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.10 OTHER THERAPEUTIC AREAS
    • TABLE 151 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2022)
    • TABLE 152 CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 153 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 154 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

9 CLINICAL TRIALS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 156 CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 SMALL MOLECULES
    • 9.2.1 INVESTMENTS IN SMALL-MOLECULE DEVELOPMENT TO SUPPORT GROWTH
    • TABLE 157 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 159 EUROPE: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 MONOCLONAL ANTIBODIES
    • 9.3.1 GROWING GOVERNMENT SUPPORT FOR MONOCLONAL ANTIBODIES TO DRIVE MARKET
    • TABLE 161 CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 162 NORTH AMERICA: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 163 EUROPE: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 164 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 VACCINES
    • 9.4.1 SHIFTING INDUSTRY FOCUS TOWARD CHRONIC DISEASE TREATMENT TO SLOW MARKET GROWTH
    • FIGURE 43 NUMBER OF CLINICAL TRIALS FOR VACCINES (2020-2023)
    • TABLE 165 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 166 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 167 EUROPE: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 168 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 CELL & GENE THERAPY
    • 9.5.1 RISING TREND OF OUTSOURCING TO FAVOR MARKET GROWTH
    • FIGURE 44 ONGOING CLINICAL TRIALS, BY PHASE AND THERAPEUTIC APPROACH (2022)
    • TABLE 169 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 170 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 171 EUROPE: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 173 CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 174 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 175 EUROPE: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 176 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

10 CLINICAL TRIALS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 177 CLINICAL TRIALS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 45 NORTH AMERICA: CLINICAL TRIALS MARKET SNAPSHOT
    • TABLE 178 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 179 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 180 NORTH AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 181 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 182 NORTH AMERICA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 183 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 US to hold largest share of North American market over forecast period
    • FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023): US TO HOLD DOMINANT SHARE
    • TABLE 184 US: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 185 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 187 US: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 188 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing clinical trial activity to support market growth
    • TABLE 189 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 190 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 191 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 CANADA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 193 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • FIGURE 47 PHARMACEUTICAL INDUSTRY R&D SPENDING IN EUROPEAN COUNTRIES, 2021 (USD MILLION)
    • TABLE 194 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 195 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 196 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 197 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 198 EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 199 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Germany to dominate clinical trials market in Europe
    • TABLE 200 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 201 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 202 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 203 GERMANY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 204 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Investments in drug discovery services to support market growth
    • FIGURE 48 UK: PHARMACEUTICAL R&D EXPENDITURE, 2018-2021 (USD MILLION)
    • TABLE 205 UK: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 206 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 207 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 208 UK: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 209 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 High number of oncology clinical trials to drive market
    • TABLE 210 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 211 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 212 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 213 FRANCE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 214 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Low drug approval times and growing number of clinical trials to boost market
    • TABLE 215 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 216 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 218 ITALY: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 219 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Rising R&D expenditure to drive market
    • FIGURE 49 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2018-2021 (USD MILLION)
    • TABLE 220 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 221 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 222 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 223 SPAIN: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 224 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 225 REST OF EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 226 REST OF EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 227 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 228 REST OF EUROPE: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 229 REST OF EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 50 ASIA PACIFIC: CLINICAL TRIALS MARKET SNAPSHOT
    • TABLE 230 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 231 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 232 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 233 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 234 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 235 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 China to dominate APAC clinical trial market
    • TABLE 236 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 237 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 238 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 239 CHINA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 240 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Strong focus on R&D activities to support growth
    • FIGURE 51 TOP THERAPEUTIC AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS IN JAPAN
    • TABLE 241 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 242 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 243 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 244 JAPAN: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 245 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Growing pharmaceutical industry to drive market
    • TABLE 246 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 247 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 248 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 249 INDIA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 250 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • FIGURE 52 BREAKDOWN OF STUDIES IN MALAYSIA, BY INTERVENTION, 2021
    • TABLE 251 REST OF ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 252 REST OF ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 253 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 254 REST OF ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 255 REST OF ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 RISING PHARMA & BIOTECH R&D TO BOOST MARKET GROWTH
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 256 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 257 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 258 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 259 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 260 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 261 MIDDLE EAST & AFRICA: CLINICAL TRIALS MARKET, BY PHASE, 2021-2028 (USD MILLION)
    • TABLE 262 MIDDLE EAST & AFRICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021-2028 (USD MILLION)
    • TABLE 263 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 264 MIDDLE EAST & AFRICA: CLINICAL TRIALS MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • TABLE 265 MIDDLE EAST & AFRICA: CLINICAL TRIALS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 53 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MARKET PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 266 CLINICAL TRIALS MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX, 2022
    • FIGURE 56 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
  • 11.6 COMPANY FOOTPRINT ANALYSIS OF TOP 25 PLAYERS
    • 11.6.1 INDUSTRY FOOTPRINT (25 COMPANIES)
    • TABLE 267 INDUSTRY FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.2 SERVICE FOOTPRINT (25 COMPANIES)
    • TABLE 268 SERVICE FOOTPRINT ANALYSIS: KEY PLAYERS
    • 11.6.3 REGIONAL FOOTPRINT (25 COMPANIES)
    • TABLE 269 REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS
  • 11.7 COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • FIGURE 57 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
    • 11.7.1 PROGRESSIVE COMPANIES
    • 11.7.2 STARTING BLOCKS
    • 11.7.3 RESPONSIVE COMPANIES
    • 11.7.4 DYNAMIC COMPANIES
  • 11.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 270 CLINICAL TRIALS MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 271 SERVICE FOOTPRINT ANALYSIS: START-UP/SMES
    • TABLE 272 REGIONAL FOOTPRINT ANALYSIS: START-UPS/SMES
  • 11.9 COMPETITIVE SCENARIO AND TRENDS
    • 11.9.1 SERVICE LAUNCHES
    • TABLE 273 CLINICAL TRIALS MARKET: SERVICE LAUNCHES (2020-2023)
    • 11.9.2 DEALS
    • TABLE 274 CLINICAL TRIALS MARKET: DEALS (2020-2023)
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 275 CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS (2020-2023)

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 12.1 KEY COMPANIES
    • 12.1.1 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 276 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 58 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
    • 12.1.2 IQVIA, INC.
    • TABLE 277 IQVIA, INC.: BUSINESS OVERVIEW
    • FIGURE 59 IQVIA, INC.: COMPANY SNAPSHOT
    • 12.1.3 ICON PLC
    • TABLE 278 ICON PLC: BUSINESS OVERVIEW
    • FIGURE 60 ICON PLC: COMPANY SNAPSHOT
    • 12.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 279 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 61 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
    • 12.1.5 SYNEOS HEALTH
    • TABLE 280 SYNEOS HEALTH: BUSINESS OVERVIEW
    • FIGURE 62 SYNEOS HEALTH: COMPANY SNAPSHOT
    • 12.1.6 WUXI APPTEC
    • TABLE 281 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 63 WUXI APPTEC: COMPANY SNAPSHOT
    • 12.1.7 CHARLES RIVER LABORATORIES
    • TABLE 282 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 64 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
    • 12.1.8 PAREXEL INTERNATIONAL CORPORATION
    • TABLE 283 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
    • 12.1.9 FORTREA, INC.
    • TABLE 284 FORTREA, INC.: BUSINESS OVERVIEW
    • FIGURE 65 FORTREA, INC.: COMPANY SNAPSHOT
    • 12.1.10 MEDPACE
    • TABLE 285 MEDPACE: BUSINESS OVERVIEW
    • FIGURE 66 MEDPACE: COMPANY SNAPSHOT
    • 12.1.11 SGS
    • TABLE 286 SGS: BUSINESS OVERVIEW
    • FIGURE 67 SGS: COMPANY SNAPSHOT
    • 12.1.12 FRONTAGE LABS
    • TABLE 287 FRONTAGE LABS: BUSINESS OVERVIEW
    • FIGURE 68 FRONTAGE LABS: COMPANY SNAPSHOT
    • 12.1.13 ACM GLOBAL LABORATORIES
    • TABLE 288 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
    • 12.1.14 ADVANCED CLINICAL
    • TABLE 289 ADVANCED CLINICAL: BUSINESS OVERVIEW
    • 12.1.15 PSI
    • TABLE 290 PSI: BUSINESS OVERVIEW
    • 12.1.16 BIOAGILE
    • TABLE 291 BIOAGILE: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 CLINICAL TRIAL SERVICE
    • 12.2.2 WORLDWIDE CLINICAL TRIALS
    • 12.2.3 PEPGRA
    • 12.2.4 CTI CLINICAL TRIAL AND CONSULTING SERVICES
    • 12.2.5 DOVE QUALITY SOLUTIONS
    • 12.2.6 FIRMA CLINICAL RESEARCH
    • 12.2.7 CELERION
    • 12.2.8 NOVOTECH
    • 12.2.9 LINICAL AMERICAS
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS